Original Article

Will the high acceptance rate of coronavirus disease 2019 vaccine in Morocco accelerate the recovery of neurosurgical practice?

Farid Zahrou, Yassine Ait M’barek, Tarik Belokda, Badr Drai, Hasna Abdourafiq, Lamia Benantar, Khalid Aniba

Department of Neurosurgery, Ibn Tofail Hospital, Mohammed VI University Hospital, Marrakesh, Morocco.

E-mail: *Farid Zahrou - farid.zahrou87@gmail.com; Yassine Ait M’barek - yassineaitm1@gmail.com; Tarik Belokda - tarikbelokda@gmail.com; Badr Drai - drbadrai2@gmail.com; Hasna Abdourafiq - hasnabdourafiq@gmail.com; Lamia Benantar - lamiaabenantar@gmail.com;
Khalid Aniba - aniba.khalid@yahoo.fr

ABSTRACT

Background: In developing countries, where there is a chronic shortage of neurosurgeons and medical infrastructures, the pandemic has taken a heavy toll on neurosurgical activities. In the absence of a curative treatment, reaching herd immunity through mass vaccination campaigns is the best hope we have of ending this pandemic. Therefore, the purpose of our study was first to assess the effect of coronavirus disease 2019 (COVID-19) outbreak on neurosurgical services of a Moroccan tertiary hospital. Secondarily, we aimed to describe current vaccination compliance rate in our country, and its impact on the recovery of neurosurgical practice.

Methods: To examine how COVID-19 challenged the neurosurgical delivery of care in our unit, we compared emergency and elective admissions during COVID-19 and pre-COVID-19 period using the registry of neurosurgery department. Second, after evaluating vaccine acceptance rates among 1463 healthcare workers and patients admitted to our hospital, we compared the number of surgeries performed in our department after implementation of a mass vaccination campaign.

Results: The overall number of procedures dropped from \( n = 197 \) (pre-COVID-19) to \( n = 150 \) during COVID-19. The number of elective surgeries declined from an average of 10.5 operations per week before COVID-19 to four surgeries per week during the COVID-19 pandemic. Conversely, an average of 3.5 emergency operations was performed each week before COVID-19 compared to 5.6 per week during the pandemic. On the other hand, our results showed that willingness to get the COVID-19 vaccine among the participants was high (81.7%) with significantly less hesitant individuals among healthcare workers \((P = 0.001)\). This successful vaccine rollout helped resuming gradually elective surgeries in our department.

Conclusion: Our study found a high acceptance rate of COVID-19 vaccines among Moroccans, which gives a glimmer of hope of restoring all our neurosurgical services. However, despite the high acceptance rate, the authorities must address concerns among hesitant individuals and raise awareness on the importance of COVID-19 immunization.

Keywords: Acceptance, Coronavirus disease 2019, Impact, Neurosurgery, Vaccine

INTRODUCTION

In December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China. Since then, the virus has...
spread in an enormous way to over 200 countries worldwide and officially declared as a pandemic by the World Health Organization (WHO) in March 2020.\(^{[10]}\) The whole world has been facing the unprecedented coronavirus health crisis over a year now.

In Morocco, the first case of COVID-19 was reported on March 2 in Casablanca, 2020.\(^{[17]}\) Although the Moroccan authorities made radical decisions to overcome the health-care system weaknesses, the virus has continued to spread across the country, increasing pressure on Moroccan hospitals. To cope with the high numbers of COVID-19 patients and the increased demand for intensive care beds, certain hospitals were prepared to manage COVID-19 cases. As a result, all surgical departments were forced to reduce elective and postponable surgeries, guaranteeing only emergency or high-priority operations. Surgeons were confronted with the challenging triage of patients into emergency, urgent and elective, which had real impact on disease progression and patient health outcomes.

To overcome this pandemic and recover from its devastating human, social and economic impact, all countries around the world try to get enough COVID-19 vaccines to immunize their communities. Morocco was no exception in this regard. Despite its limited resources, the North African kingdom has one of the most advanced vaccination programs. The country launched a nationwide vaccination campaign on January 28, aiming to vaccinate 80% of its citizens.\(^{[21]}\) However, Morocco, like other low- and middle-income countries, is facing difficulties in gaining access to the vaccines, as wealthier countries make bilateral deals and drive up the prices. Consequently, this inequality increases the risk of the spread of the virus in our country, given its current status of health-care system and its limited resources.\(^{[8]}\)

However, utility of vaccine campaigns is not merely dependent on vaccine availability and affordability. In fact, vaccine hesitancy remains a global challenge even among healthcare workers and appears to have a decisive role in the successful control of the pandemic.\(^{[20]}\) This could delay the restoration of elective surgeries and hospital activities. Identifying factors associated with vaccine acceptance is crucial to address COVID-19 vaccine hesitancy and guide interventional measures aimed at increasing this awareness in the general population. To the best of our knowledge, there is currently no study that highlights COVID-19 vaccine acceptance in Morocco. Therefore, the purpose of our study was first to assess the effect of COVID-19 outbreak on neurosurgical services of our hospital compared to the pre-COVID-19 period. And secondarily, we aimed to evaluate current vaccination compliance rates among healthcare workers as well as patients admitted to our hospital, and to evaluate the early impact of the national vaccination campaign on neurosurgical practice in our university hospital.

**MATERIALS AND METHODS**

**Study design and data collection**

To assess the impact of the COVID-19 pandemic on neurosurgical practice in Morocco, a single-center retrospective epidemiological study was conducted in our hospital, which is one of the major hospitals in our city, based in an urban area of 1.3 million inhabitants.

First of all, we described the global epidemiology of COVID-19 in our city based on the COVID-19 online database created by the Moroccan Ministry of Health.\(^{[17]}\) At the beginning, the government selected the Pasteur Institute of Morocco as COVID-19 national referral laboratory. Then, to increase the screening rate for the COVID-19 virus, the Ministry of Health selected other laboratories from the beginning of April 2020 between March 2, 2020, and June 28, 2021. 6,273,223 tests were carried out, for a rate of approximately 10,000 tests per day.\(^{[3]}\) However, Morocco’s testing capacity for COVID-19 is 10 times lower than high-income countries, which hardly gives a clear picture of the real situation of the pandemic in the country.\(^{[35]}\)

To examine how COVID-19 challenged the neurosurgical delivery of care in our unit, we compared emergency and elective admissions during COVID-19 and pre-COVID-19 period using the registry of neurosurgery department. All neurosurgical procedures performed in our department between March 2, 2020, and June 28, 2020, were enrolled in our study. Data collected were: the surgery date, the number, and the types of surgical procedures performed during the study period. We also classified patients according to surgical urgency. Urgent cases included:

1. Brain tumor with cerebral herniation on MRI or worsening symptoms or acute hydrocephalus
2. Skull base tumors with worsening symptoms or visual disturbances
3. Acute hydrocephalus, shunt malfunction, and ruptured spina bifida
4. Aneurysm rupture or other acute vascular diseases
5. Neurotrauma, vertebro-medullary trauma, cauda equina syndrome, acute spinal cord compression, and paralyzing disk herniation.

Apart from these emergencies, the rest of the patients were included in elective surgery group. These data were then compared to those obtained in the “pre-COVID-19 period” (from March 2, 2019, to June 28, 2019), to assess the impact of the pandemic.

Second, to evaluate vaccine acceptance rates among Moroccan population, we distributed an anonymous questionnaire from January 1, 2021, to January 31, 2021, just before the beginning of the mass vaccination program in Morocco to healthcare workers and patients admitted to our
hospital within the study period. The questions were related to socio-demographic characteristics (age, gender, area of residence, marital status, and parenthood status), education level, employment status, financial status, underlying diseases, perceptions, risk factors for COVID-19, and willingness to get COVID-19 vaccination. With reference to previous studies, five response options were provided: very unlikely, somewhat unlikely, somewhat likely, very likely, and unsure. Then, participants who responded “very unlikely” or “somewhat unlikely” or “unsure” were presented with specific questions regarding the reasons for vaccine hesitancy. In total, responses from 243 healthcare workers and 1220 patients were collected. All participants provided informed consent before their participation.

Finally, to assess the early impact of the national vaccination program on neurosurgical activity in our hospital, we compared elective and urgent procedures performed in our department before (from March 2, 2020, to June 28, 2020) and after implementation of a mass vaccination campaign against COVID-19 in Morocco (from March 2, 2021, to June 28, 2021).

Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences version 25. Mean and standard deviation was calculated to describe continuous variables while numbers and percentages were used for categorical variables. Descriptive analysis and Chi-square tests were used to evaluate the data and assess the statistical significance of observed differences between cohorts before and during the COVID-19 pandemic. P < 0.05 was considered significant.

RESULTS
COVID-19 in Morocco
Since the report of the first case on March 2, 2020, and until June 28, 2021, the cumulative number of confirmed cases reached 529,895 cases with 9,283 deaths and a cumulative incidence of 1456, 3 per 100,000 inhabitants. Morocco’s quick and strict response to the pandemic was relatively effective at the beginning in containing the spread of the virus. However, after easing the containment measures, the situation in Morocco has deteriorated. In fact, the numbers of new cases and deaths have reached the highest levels ever recorded since the start of the pandemic, mainly related to professional and familial clusters. In fear of a new wave of COVID-19 infections that could threaten months of progress, and especially with the emergence of the Indian coronavirus variant, the Moroccan authorities banned flights with most countries and kept a night curfew in place to counter the spread of new variants.

Marrakech is the fourth largest city in the Kingdom with 1329,850 inhabitants. The Red City was ranked 9th best global destination in 2019 by Trip Advisor. On March 10, the health authorities announced the first case in Marrakesh. It was a French tourist who arrived in Morocco on March 7. Early during the outbreak of the pandemic, Marrakech-Safi region turned out to be one of the most affected regions with an average of over 100 daily new cases. This is why the city is classified as zone 2. In fact, the Moroccan provinces are categorized into two zones depending on the level of COVID-19 risk present in the region, and these categories are updated on a weekly basis.

Hospital organization and the phases of the pandemic at our Hospital
After announcing the country’s first case of COVID-19 on March 2, a full reorganization of the health system was initiated countrywide to overcome the chronic weakness of medical infrastructure and the lack of resources. We divided our experience during this period into two phases: phase 1 (March 2–27, 2020) in which the activity remained almost normal and phase 2 (March 28 – June 28, 2020) during which Mohammed VI university hospital was completely devoted to COVID-19 admissions, while our hospital was assigned to manage all non-COVID patients with urgent neurosurgical pathology. At the beginning of phase 2, our hospital, which became the only hospital in the region admitting neurosurgery patients, had to be on high alert to contain the influx of patients and to ensure safety of healthcare providers and neurosurgical patients.

Emergency and elective neurosurgical operations performed before and during COVID-19 at our hospital
We divided our patients into two groups: those requiring immediate surgical procedure and those waiting for scheduled surgery before and during COVID-19 pandemic. The total number of procedures dropped from n = 197 (pre-COVID-19) to n = 150 during COVID-19. Conversely, the number of emergency operations increased during COVID-19 (n = 95) compared to pre-COVID-19 period (n = 58). Before the pandemic, an average of 3.4 emergency operations was performed each week compared to 5.6 per week during COVID-19 [Table 1].

Concerning elective surgery, the overall number of operations declined from an average of 10.5 elective operations per week before COVID-19 to 7, 25 per week during phase 1 and 2, 9 per week during phase 2 [Table 1]. Regarding the distribution of operations per neurosurgical subspecialty, there was a statistically significant decrease during COVID-19 compared to the pre-COVID-19 period in tumor surgery (pre-COVID-19 n = 64, COVID-19 n = 34, P = 0.04) and
endoscopic surgery (pre-COVID-19 \( n = 47 \), COVID-19 \( n = 22 \), \( P = 0.034 \)). In contrast, there was a statistically significant increase in spine surgery (pre-COVID-19 \( n = 21 \), COVID-19 \( n = 30 \), \( P = 0.01 \)) and trauma surgery (pre-COVID-19 \( n = 29 \), COVID-19 \( n = 38 \), \( P = 0.021 \)). No differences were reported in other neurosurgical categories between the COVID-19 period and the reference [Table 1].

**Vaccine acceptance**

The analysis set consisted of 1463 participants. Among the participants, 98 (6.7%) were medical doctors, 145 (9.9%) were nurses or paramedics, and 1220 (83.4%) were patients admitted to our hospital during the study period. The main characteristics of the participants are summarized in [Table 2]. Among study participants, 321 (21.9%) had been previously infected with COVID-19 and 86 (5.9%) had lost a relative or close friend due to COVID-19. Regarding perception toward COVID-19 pandemic, only 125 (8.5%) patients believed that the severity of COVID-19 infection was low and approximately a third of the participants agreed that the media coverage of the pandemic was exaggerated [Table 3].

Overall, willingness to get the COVID-19 vaccine was high, 45.9% of the participants were very likely and 35.8% were likely to be vaccinated, while 5.8% were undecided. Further analysis revealed that vaccine acceptance rates were significantly higher among healthcare workers (90.6%) than patients (80%; \( P = 0.001 \)). Furthermore, the main reasons for vaccine hesitancy were fears of the vaccine's safety and concerns over efficacy and future unknown effects of the vaccine [Table 4].

**The early impact of COVID-19 vaccination campaign on neurosurgical practice**

Our findings showed that the total number of procedures increased from \( n = 150 \) (before vaccination) to \( n = 179 \) after starting a mass vaccination campaign in our country. However, the number of urgent operations decreased after implementation of the vaccination campaign to approach the average number found in the pre-COVID 19 period. Concerning elective surgery, the number of procedures increased from an average of 4 elective operations per week to 7.5 per week after starting the vaccination [Table 5].

The analysis of the distribution of operations per neurosurgical subspecialty revealed a statistically significant increase after implementation of the national vaccination campaign in tumor surgery (\( P = 0.049 \)) and endoscopic surgery (\( P = 0.019 \)). In contrast, we noted a statistically significant decrease in trauma surgeries (\( P = 0.001 \)) and spine surgery (\( P = 0.04 \)) after starting COVID-19 vaccination (\( P = 0.001 \)) [Table 5].

**DISCUSSION**

**COVID-19: A global health crisis**

The coronavirus COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War Two. Since its emergence in Asia in December 2019, the virus has spread to every continent and nearly every country on earth. In the absence of effective treatments, many countries have responded by implementing several non-pharmaceutical interventions to halt the spread of the virus and limit the number of fatalities: social distancing, cancellation of public events, school closures, workplace closures, isolation and quarantine for infected people, and internal and international travel restrictions. The effectiveness of these containment measures remains unclear, but the number of reported cases in many countries increased rapidly after the release of lockdown measures. As of Monday May 31, 2021, over 170 million coronavirus cases have been reported and over 3.6 million people have died of COVID-19.
### Table 2: Characteristics of the participants.

|                          | Total (n=1463) | Healthcare workers (n=243) | Patients (n=1220) | P-value |
|--------------------------|----------------|---------------------------|-------------------|---------|
| Gender, n (%)            |                |                           |                   |         |
| Male                     | 625 (42.7)     | 105 (43.2)                | 520 (42.6)        | 0.8     |
| Female                   | 838 (57.3)     | 138 (56.8)                | 700 (57.4)        |         |
| Age, mean±SD, years      | 46.5±13.7      | 39.2±10.5                 | 47.9±13.7         | <0.001  |
| Marital status, n (%)    |                |                           |                   |         |
| Married                  | 676 (46.2)     | 130 (53.5)                | 546 (44.8)        | 0.01    |
| Not married              | 787 (53.8)     | 113 (46.5)                | 674 (55.2)        |         |
| Parenthood status, n (%) |                |                           |                   |         |
| Parent                   | 680 (46.5)     | 104 (42.8)                | 576 (47.2)        | 0.2     |
| Childless                | 783 (53.5)     | 139 (57.2)                | 644 (52.8)        |         |
| Education level, n (%)   |                |                           |                   |         |
| Illiterate               | 210 (14.3)     | 0 (0)                     | 210 (17.2)        | <0.001  |
| Elementary and middle school | 361 (24.7)   | 0 (0)                     | 361 (29.6)        |         |
| High school              | 424 (29)       | 0 (0)                     | 424 (34.8)        |         |
| Post secondary studies   | 468 (32)       | 243 (100)                 | 225 (18.4)        |         |
| Geographical origin, n (%)|              |                           |                   |         |
| Urban                    | 758 (51.8)     | 243 (100)                 | 515 (42.2)        | <0.001  |
| Rural                    | 705 (48.2)     | 0 (0)                     | 705 (57.8)        |         |
| Underlying diseases, n (%)|              |                           |                   |         |
| Yes                      | 812 (55.5)     | 50 (20.6)                 | 762 (62.5)        | <0.001  |
| No                       | 651 (44.5)     | 193 (79.4)                | 458 (37.5)        |         |
| Financial difficulties, n (%)|              |                           |                   |         |
| Yes                      | 886 (60.6)     | 32 (13.2)                 | 854 (70)          | <0.001  |
| No                       | 577 (39.4)     | 211 (86.8)                | 366 (30)          |         |
| Fixed monthly income, n (%)|              |                           |                   |         |
| Yes                      | 555 (37.9)     | 235 (96.7)                | 320 (26.2)        | <0.001  |
| No                       | 908 (62.1)     | 8 (3.3)                   | 900 (73.8)        |         |

### Table 3: Risk factors and perceptions of the COVID-19 pandemic.

|                          | Total (n=1463) | Healthcare workers (n=243) | Patients (n=1220) | P-value |
|--------------------------|----------------|---------------------------|-------------------|---------|
| Need to leave the house quite often for work, n (%)|                |                           |                   |         |
| Yes                      | 801 (54.8)     | 243 (100)                 | 558 (45.7)        | <0.001  |
| No                       | 662 (45.2)     | 0 (0)                     | 662 (54.3)        |         |
| Previously infected with COVID-19, n (%)|                |                           |                   |         |
| Yes                      | 321 (21.9)     | 76 (31.3)                 | 245 (20.1)        | <0.001  |
| No                       | 1142 (78.1)    | 167 (68.7)                | 975 (79.9)        |         |
| Relative or close friend died from COVID-19, n (%)|                |                           |                   |         |
| Yes                      | 86 (5.9)       | 14 (5.8)                  | 72 (5.9)          | 0.9     |
| No                       | 1377 (94.1)    | 229 (94.2)                | 1148 (94.1)       |         |
| Perceived severity of COVID-19 infection, n (%)|                |                           |                   |         |
| Low                      | 125 (8.5)      | 0 (0)                     | 125 (10.2)        | <0.001  |
| Middle                   | 462 (31.6)     | 61 (25.1)                 | 401 (32.9)        |         |
| High                     | 876 (59.9)     | 182 (74.9)                | 694 (56.9)        |         |
| Is media coverage of the pandemic exaggerated? n (%)|                |                           |                   |         |
| Yes                      | 507 (34.7)     | 85 (35)                   | 422 (34.6)        | 0.9     |
| No                       | 956 (65.3)     | 158 (65)                  | 798 (65.4)        |         |
| Source of information related to the COVID-19 pandemic, n (%)|                |                           |                   |         |
| I have no information   | 180 (12.3)     | 0 (0)                     | 180 (14.8)        | <0.001  |
| Newspaper                | 53 (3.6)       | 0 (0)                     | 53 (4.3)          |         |
| TV                       | 506 (34.6)     | 0 (0)                     | 506 (41.5)        |         |
| Internet and Social media | 304 (20.8)   | 30 (12.3)                 | 274 (22.4)        |         |
| World health organization | 33 (2.3)       | 33 (13.6)                | 0 (0)             |         |
| More than one source     | 387 (26.4)     | 180 (74.1)                | 207 (17)          |         |
Table 4: Willingness to get the COVID-19 vaccine and reasons for vaccine hesitancy.

| Willingness to get vaccination, n (%) | Total (n=1463) | Healthcare workers (n=243) | Patients (n=1220) | P-value |
|-------------------------------------|----------------|---------------------------|-------------------|---------|
| Very unlikely                       | 82             | 9                         | 73                | 0.001   |
| Somewhat unlikely                   | 101            | 3                         | 98                |         |
| Somewhat likely                     | 524            | 93                        | 431               |         |
| Very likely                         | 672            | 127                       | 545               |         |
| Unsure                              | 84             | 11                        | 73                |         |

Concerns regarding COVID-19 vaccine, n (%)

| Concerns regarding COVID-19 vaccine, n (%) | Total (n=1463) | Healthcare workers (n=243) | Patients (n=1220) | P-value |
|-------------------------------------------|----------------|---------------------------|-------------------|---------|
| Doubted efficacy                          | 256 (88.3)     | 21 (91.3)                 | 235 (88)          | <0.001  |
| Safety                                    | 261 (90)       | 19 (82.6)                 | 242 (90.6)        |         |
| Accessibility                             | 88 (30.3)      | 0 (0)                     | 88 (32.9)         |         |
| Quality control                           | 51 (17.6)      | 11 (47.8)                 | 40 (15)           |         |
| Future effects                            | 194 (66.9)     | 8 (34.8)                  | 186 (69.7)        |         |
| Pregnancy                                 | 19 (6.5)       | 5 (21.7)                  | 14 (5.2)          |         |
| Lack of trust in vaccines                 | 97 (33.4)      | 2 (8.7)                   | 95 (35.6)         |         |

Table 5: Number of urgent and elective surgeries and diagnosis category before and after implementation of the national COVID-19 vaccination campaign.

| Variable                      | Before vaccination (n=150) | After vaccination (n=179) | P-value |
|-------------------------------|---------------------------|---------------------------|---------|
| Procedures per week, median  |                           |                           |         |
| Urgent surgeries              | 5.6                       | 3.5                       | 0.004*  |
| Elective surgeries            | 4                         | 7.5                       | 0.0001* |
| Diagnosis category, n (%)    |                           |                           |         |
| Trauma                        | 38 (25.3)                 | 21 (11.7)                 | 0.001*  |
| Tumor                         | 34 (22.7)                 | 58 (32.4)                 | 0.049*  |
| Vascular                      | 8 (5.3)                   | 8 (4.5)                   | 0.71    |
| Endoscopic                    | 22 (14.7)                 | 45 (25.1)                 | 0.02*   |
| Spine                         | 30 (20)                   | 21 (11.7)                 | 0.04*   |
| Hydrocephalus                 | 12 (8)                    | 14 (7.8)                  | 0.95    |
| Congenital                    | 5 (3.3)                   | 10 (5.6)                  | 0.32    |
| Infection                     | 1 (0.6)                   | 2 (1.1)                   | 0.66    |

*Statistically significant difference

worldwide. The USA, India, and Brazil have recorded the highest number of confirmed cases, followed by France, Turkey, Russia, and the United Kingdom (UK). Moreover, the number of cases and deaths in Africa has increased at a faster rate in the last weeks compared to the other waves. This is driven by several factors including public fatigue, social mixing, ineffective use of public health and social measures, vaccine inequity, and the spread of new variants. In addition to vaccine inequities, vaccine acceptance appears to be the next challenge in the fight against COVID-19.

Neurosurgical impact of COVID-19 outbreak

The COVID-19 pandemic is a health crisis of unprecedented proportions that has taken a heavy toll on various aspects of the society. Health systems are facing the most serious global pandemic crisis in a century. To contain the spread of novel coronavirus COVID-19 and reduce the pressure on health systems, numerous guidelines were published by international surgical societies including neurosurgical societies. In developing countries including Morocco, where there is a chronic shortage of neurosurgeons, nurses or other skilled health workers, any additional pressure on health-care systems arising from the looming pandemic becomes almost unmanageable. Many of
the recommendations published by other neurosurgical centers could not be achieved given the local limitations and resources.\(^\text{16}\) According to a survey about how Africa’s neurosurgical community has been affected by COVID-19, only 52 (16.5\%) of the respondents stated they had a specific COVID-19 neurosurgery policy and only 49\% felt that their response plans were satisfactory for their neurosurgical services.\(^\text{19}\)

To manage vital health-care resources during this public health emergency, national and international societies suggested stopping all elective activity and maintaining only emergent and urgent procedures.\(^\text{2,6}\) According to an international survey, neurosurgical activity was significantly reduced in most centers (79\%).\(^\text{13}\) In our department, we did not postpone all elective neurosurgeries during phase 1, because we have a long list of patients waiting for surgery. However, during phase 2, we reduced the number of elective surgeries to handle the influx of emergency cases. The decrease in elective surgeries can also be explained by the shortage of intensive care unit (ICU) beds for neurosurgery patients, since most beds were reserved for COVID-19 patients and the poor availability of personal protective equipment (PPE) in the early phase of the pandemic. Moreover, the unprecedented increase in the demand for intensive care services due to the COVID-19 pandemic involved a rapid redeployment of healthcare staff, including neurosurgeons, to these units.

On the other hand, our findings showed that the number of urgent surgeries performed in our department increased during the pandemic, compared to the pre-COVID 19 period. This can be explained by the fact that our department became the only hospital in the region admitting neurosurgery patients, since the other hospitals were devoted to COVID-19 cases. We also noticed that during the pandemic the number of neurotrauma cases increased by approximately 10\% compared to the pre-COVID-19 period, although road traffic accidents declined during lockdown. This can be explained by the significant increase of interpersonal violence documented by many reports, the increased unstructured time and the socioeconomic impact of the pandemic resulting in higher unemployment.\(^\text{1,24}\)

Neurosurgical training and education have also been significantly affected by this pandemic. In fact, neurosurgery departments worldwide have been forced to restructure their training programs to handle this healthcare emergency. According to a continental survey on the impact of COVID-19 on neurosurgical training in Africa, only 41\% of the respondents had received training in COVID-19, although many African countries do not have formal neurosurgery training schemes or fellowship opportunities.\(^\text{7}\) Similar findings were reported by Wittayanakorn et al. in Southeast Asia\(^\text{31}\) and Zoia et al. in Italy.\(^\text{14}\) In our department, we adopted a new shift scheduling system to decrease transmission among colleagues and to preserve the workforce. This also helped in optimizing PPE supplies in health-care settings. We divided the team into three groups that switch coverage each week, Group 1 for emergency cases (faculty, senior resident, and junior resident), Group 2 for elective surgeries (faculty, senior resident, and junior resident), and Group 3 forward activities. The rest of the team stay at home remotely providing telesupervision, consultation, and arrange different virtual teaching programs. They also replace those who show COVID-19 symptoms to ensure continuity of care.

In light of the above, successful control of COVID-19 infections and deaths at the international level seems to be important in ensuring continuation of neurosurgical training and provision of neurosurgical services. This objective can only be achieved through mass vaccination campaigns to reach herd immunity. However, despite the huge efforts made by health authorities, a major hindrance can be related to vaccine hesitancy.

### Vaccine hesitancy

Based on the Strategic Advisory Group of Experts on Immunization, vaccine hesitancy is the term used to describe: “delay in acceptance or refusal of vaccination despite availability of vaccination services.”\(^\text{14}\) It remains a barrier to full population inoculation against highly infectious diseases. Even before the emergence of SARS-CoV-2, the WHO had already highlighted vaccine hesitancy as one of the ten leading threats to global health.\(^\text{12}\) Factors that affect the attitude toward acceptance of vaccination are complex and can vary geographically. They include complacency, convenience, and confidence.\(^\text{27}\)

Our survey results found high vaccine acceptance rates among our healthcare workers and our patients. In fact, the vast majority of the participants (81.7\%) are willing to take up a COVID-19 vaccine if offered. While only 18.3\% are still hesitant or refusing to get vaccinated. The previous studies have also studied this global phenomenon and revealed the existence of regional variability in COVID-19 vaccine acceptance rates. According to a systematic review assessing the acceptances rates in different countries worldwide, the highest vaccine acceptance rates (>90\%) among the general population were reported by four studies from Ecuador (97.0\%), Malaysia (94.3\%), Indonesia (93.3\%), and China (91.3\%). On the opposite, the lowest vaccine acceptance rates (<60\%) among the general public were found in seven studies from Kuwait (23.6\%), Jordan (28.4\%), Italy (53.7\%), Russia (54.9\%), Poland (56.3\%), US (56.9\%), and France (58.9\%). However, this topic has not been explored to a large degree in Africa. Therefore, more studies are needed to address COVID-19 vaccine hesitancy in this continent.\(^\text{28}\)
Finally, the main reasons for vaccine hesitancy in our study were fears of the vaccine's safety and concerns over efficacy and future unknown effects of the vaccine. The same concerns were reported by Dror et al. in Israel\textsuperscript{12} and Robertson et al. in the UK.\textsuperscript{26}

The early impact of the COVID-19 vaccination campaign: Signals of hope

Morocco launched its ambitious COVID-19 vaccination campaign on January 28, 2021, seeking to vaccinate 80\% of its adults. The king of Morocco, as the spiritual leader of the nation, was the first Moroccon to be vaccinated, giving an essential boost to the vaccination campaign. Despite monumental challenges, the African country is among the world's pioneers in vaccinating its population against COVID-19. On June 28, 2021, the total number of people fully vaccinated against COVID-19 in Morocco reached 895,4030 (about 25.6\% of Moroccan population), while a total of 990,882 first doses of COVID-19 vaccines have been administered.\textsuperscript{3} The Moroccan vaccination campaign has clearly been rapid and effective compared to other African countries, where the rates of vaccination did not exceed 1\%. However, is it possible to already assess the positive effects of the COVID-19 vaccination while the country is facing a new wave?

In fact, it is too early to evaluate the real impact of the vaccination campaign. However, the ministry of health has carried out a comparative analysis on the epidemiological situation in Morocco and the UK based on the number of cases, the vaccination rate and the number of deaths. This study, which covered the period from January to August 2021, showed that, despite rising COVID-19 cases, the infection fatality rate of the disease is less than in the early stages of the pandemic thanks to vaccination. As of August 6, 2021, the case fatality rate was 0.6\% in Morocco for a vaccination rate of 29.4\% versus 0.2\% in the UK for a vaccination rate of 57.9\%.\textsuperscript{17}

Concerning the early impact of the COVID-19 vaccination campaign on neurosurgical activities in our country, our findings showed that the number of elective surgeries performed in our department increased after the start of the vaccination campaign. This can be explained by several factors. First of all, the number of COVID-19 patients admitted to hospital ICUs decreased after the implementation of the vaccination campaign. Furthermore, the relative stability of the epidemiological situation in Morocco allowed surgeons to go back to their departments and to resume their professional activities. As mentioned above, to minimize the risk of acquiring COVID-19 infection while managing patients, we reorganized our surgical team into three groups. However, we resumed the traditional staff scheduling after all the team members got fully vaccinated. Therefore, our hospital was given the green light to gradually begin ramping-up elective surgeries and procedures. Nevertheless, vaccination alone is not enough to contain the pandemic. The healthcare workers should respect safety measures to avoid exposure to nosocomial infection for both patients and surgical teams.

Strengths and limitations of our study

Our study has several strengths. First, our study provided answers to two topics. On one hand, it revealed the neurosurgical impact of COVID-19 pandemic in Morocco. Moreover, on the other hand, it highlighted the high acceptance rate of COVID-19 vaccine among our participants, which can help controlling the pandemic, to restore all neurosurgical services. Second, to the best of our knowledge, this is the first study in Morocco to assess the acceptance regarding COVID-19 vaccines and the reasons why a COVID-19 vaccine would be refused. It also did so just before the launch of the vaccination campaign in Morocco on January 28, 2021. The country is now rolling out a successful vaccination program starting with the oldest and most vulnerable population groups. Finally, our survey covered healthcare workers as well as patients and compared responses to identify differences.

There are also limitations of our study which should be noted. First of all, concerning neurosurgical impact of the pandemic, the number of patients included was small due to the relatively short study period. A larger period could have been investigated but would not have been more relevant to evaluate the impact of the pandemic on neurosurgical activities. Moreover, the study was retrospectively performed in a single center and may therefore involve selection bias. We further did not analyze the impact of COVID-19 on patient outcomes because we could not exclude the possibility of unmeasured confounding factors. Another limitation is Morocco’s infection rates during the early phase of the COVID-19 pandemic which were low compared with those of other countries.

CONCLUSION

The whole world is experiencing an unprecedented health crisis that has profoundly impacted all aspects of society, including neurosurgical activities. Our results highlighted how difficult is managing neurosurgical services during this pandemic in developing countries which cannot support any additional pressure on their health care systems. However, our study also found a high rate of acceptance of COVID-19 vaccines among Moroccans, which gives a glimmer of hope. Despite the high acceptance rate, the Moroccan authorities must address concerns among hesitant individuals and raise awareness on the importance of COVID-19 immunization, so that we can return soon to our normal life.
Zahrou, et al.: Recovery of neurosurgical practice after coronavirus disease 2019

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent.

**Financial support and sponsorship**

Publication of this article was made possible by the James I. and Carolyn R. Ausman Educational Foundation.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. About 2 Million Guns Were Sold in the U.S. as Virus Fears Spread-The New York Times; 2020. Available from: https://www.nytimes.com/interactive/2020/04/01/business/coronavirus-gun-sales.html [Last accessed on 2020 Dec 24].
2. American College of Surgeons. COVID-19: Recommendations for Management of Elective Surgical Procedures. United States: American College of Surgeons; 2020. Available from: https://www.facs.org/covid-19-clinical-guidance/elective-surgery [Last accessed on 2020 Dec 24].
3. Available from: http://www.covidmaroc.ma/documents/bulletin/31.5.21.covid-19.pdf [Last accessed on 2021 Jun 20].
4. Available from: https://www.extranet.who.int/pqweb/sites/default/files/documents/status_covid_vax_02july2021.pdf [Last accessed on 2021 Jul 11].
5. Bouzrou S. Marrakech Parmi les 10 Meilleures Destinations Touristiques du Monde en 2019, Maroc Diplomatique; 2019. Available from: https://www.maroc-diplomatique.net/marrakech-parmi-les-10-meilleures-destinations-touristiques-du-monde-en-2019 [Last accessed on 2020 Dec 14].
6. Cenzato M, DiMeco F, Fontanella M, Locatelli D, Servadei F. Neurosurgery in the storm of COVID-19: Suggestions from the Lombardy region, Italy (ex malo bonum). J Neurosurgery 2020;133:1-2.
7. Cheserem JB, Esene IN, Mahmud MR, Kalangu K, Sanoussi S, Musara A, et al. A continental survey on the impact of COVID-19 on neurosurgical training in Africa. World Neurosurg 2021;147:e8-15.
8. Cioffia A, Cioffib F. COVID-19 vaccine: Risk of inequality and failure of public health strategies. Ethics Med Public Health 2021;17:100653.
9. Coronavirus: Le Maroc Allege Son Confinement, LEFIGARO; 2021. Available from: https://www.lefigaro.fr/flash-actu/coronavirus-le-maroc-allege-son-confinement-20200620 [Last accessed on 2021 Jun 10].
10. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157-60.
11. Dhandapani M, Dhandapani S. Challenges posed by COVID-19 and neurosurgical nursing strategies in developing countries. Surg Neurol Int 2020;11:441.
12. Dror AA, Eisenbach N, Taibler S, Morozov NG, Mizrachi M, Zigrin A, et al. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur J Epidemiol 2020;35:775-9.
13. Fontanella MM, de Maria L, Zanin L, Saraceno G, di Bergamo LT, Servadei F, et al. Neurosurgical practice during the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pandemic: A worldwide survey. World Neurosurg 2020;139:e818-26.
14. Ganau M, Netuka D, Broekman M, Zoia C, Tsiankace, Schweke M, et al. Neurosurgeons and the fight with COVID-19: A position statement from the EANS individual membership committee. Acta Neurochir (Wien) 2020;162:1777-82.
15. Kavanagh MM, Erondu NA, Tomori O, Dzau VJ, Okiro EA, Maleche A, et al. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet 2020;395:1735-8.
16. Lakhdar F, Benzamgou M. Letter: Neurosurgery at war with the COVID-19 pandemic: Patient’s management from an African neurosurgical center. Acta Neurochir (Wien) 2020;162:1787-8.
17. Le Portail Officiel du Coronavirus au Maroc; 2021. Available from: http://www.covidmaroc.ma/pages/accueillfr.aspx [Last accessed on 2021 May 11].
18. MacDonald NE, Sage Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015;33:4161-4.
19. Mahmud MR, Cheserem B, Esene IN, Kalangu K, Sanoussi S, Musara A, et al. The impact of COVID-19 on neurosurgical services in Africa. World Neurosurg 2021;146:e747-54.
20. Nayar RK, Nair AT, Shaffi M, Swarnam K, Kumar A, Abraham M, et al. Methods to overcome vaccine hesitancy. Lancet 2019;393:1203-4.
21. Nhaili S. Le Roi Lancera la Campagne de Vaccination Anti-COVID ce Jeudi 28 Janvier-Medias24; 2021. Available from: https://www.medias24.com/2021/01/27/le-roi-lancera-la-campagne-de-vaccination-anti-covid-ce-jeudi-28-janvier [Last accessed on 2021 May 15].
22. Otu A, Osifo-Dawodu E, Atuahbe P, Agogo E, Ebenso B. Beyond vaccine hesitancy: Time for Africa to expand vaccine manufacturing capacity amidst growing COVID-19 vaccine nationalism. Lancet Microbe 2021;2:e347-8.
23. Ouambi OL, Kessely YC, Toudjingar F, Beidjam OA, Goli SO, Mba NJ, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun 2021;94:41-50.
24. Qasim Z, Sjoholm LO, Volgraf J, Sailes S, Nance ML, Perks DH, et al. Trauma center activity and surge response during the early phase of the COVID-19 pandemic-the Philadelphia story. J Trauma Acute Care Surg 2020;89:821-8.
25. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al. Coronavirus pandemic (COVID-19). Our World Data 2020. Available from: https://www.ourworldindata.org/coronavirus [Last accessed on 2021 Jun 22].
26. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun 2021;94:41-50.
27. SAGE Working Group on Vaccine Hesitancy, Report of the SAGE Working Group on Vaccine Hesitancy; 2021. Available from: https://www.who.int/immunization/sage/meetings/2014/october/1_report_working_group_vaccine_
hesitancy_final.pdf [Last accessed on 2021 Jun 12].

28. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines 2021;9:160.

29. Setyono H, Alifianto U, Wijanarko F, Ramadhana GA, Putra GS, Putra MD, et al. The impact of the pandemic on neurosurgical services: A study from a coronavirus disease 2019 referral hospital in Surakarta. Surg Neurol Int 2021;12:128.

30. Tan Y, Wang J, Zhao K, Han L, Zhang H, Niu H, et al. Preliminary recommendations for surgical practice of neurosurgery department in the central epidemic area of 2019 Coronavirus infection. Curr Med Sci 2020;40:1-4.

31. Wittayanakorn N, Nga VD, Sobana M, Bahuri NF, Baticulon RE. Impact of COVID-19 on neurosurgical training in Southeast Asia. World Neurosurg 2020;144:e164-77.

32. World Health Organization. Ten Threats to Global Health in 2019. Geneva: World Health Organization; 2021. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 [Last accessed on 2021 Jun 11].

33. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel Coronavirus from patients with pneumonia in China. N Engl J Med 2020;382:727-33.

34. Zoia C, Raffa G, Somma T, Pepa GM, La Rocca G, Zoli M, et al. COVID-19 and neurosurgical training and education: An Italian perspective. Acta Neurochir (Wien) 2020;162:1789-94.

How to cite this article: Zahrou F, M’barek YA, Belokda T, Drai B, Abdourafiq H, Benantar L, et al. Will the high acceptance rate of coronavirus disease 2019 vaccine in Morocco accelerate the recovery of neurosurgical practice? Surg Neurol Int 2021;12:486.